Cariprazine Hydrochloride is used for treating major depressive disorder, bipolar disorder, and schizophrenia. It was first introduced by Abbvie Inc in its drug Vraylar on Sep 17, 2015. 3 different companies have introduced drugs containing Cariprazine Hydrochloride.

Cariprazine Hydrochloride Patents

Given below is the list of patents protecting Cariprazine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Vraylar	US7737142	(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists	Sep 17, 2029	Abbvie
Vraylar	US7943621	Salts of piperazine compounds as D3/D2 antagonists	Dec 16, 2028	Abbvie
Vraylar	USRE47350	Pharmaceutical formulations containing dopamine receptor ligands	Jul 16, 2029	Abbvie
Vraylar	USRE49110	Pharmaceutical formulations containing dopamine receptor ligands	Jul 16, 2029	Abbvie
Vraylar	USRE49302	Pharmaceutical formulations containing dopamine receptor ligands	Jul 16, 2029	Abbvie

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cariprazine Hydrochloride's patents.

Latest Legal Activities on Cariprazine Hydrochloride's Patents

Given below is the list recent legal activities going on the following patents of Cariprazine Hydrochloride.

Event	Date	Patent/Publication
Critical Events This Week
Payment of Maintenance Fee, 12th Year, Large Entity	08 Nov, 2022	US7943621
Payment of Maintenance Fee, 12th Year, Large Entity	15 Dec, 2021	US7737142
Patent Term Extension Certificate	04 Dec, 2019	US7737142
Post Issue Communication - Certificate of Correction	09 Jun, 2019	US7737142
Mail Certificate of Correction Memo	05 Jun, 2019	US7737142
Certificate of Correction Memo	04 Jun, 2019	US7737142
Notice of Final Determination -Election Required	17 Apr, 2019	US7737142
Notice of Final Determination -Election Required	17 Apr, 2019	US7943621
Payment of Maintenance Fee, 8th Year, Large Entity	06 Nov, 2018	US7943621
FDA Final Eligibility Letter	10 Oct, 2018	US7737142

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳